Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | May 14, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date May 14, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-05-13 | Direct | 9,149 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 9,149 · Balance 9,149 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 14, 2026 22:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 9,149 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001909592-26-000002 · ownership.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,149 Underlying: Common Stock · 9,149 shares Expires 2036-05-13 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 2,775 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001411690-25-000064 · wk-form4_1749761396.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 2,775 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:23 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001411690-24-000037 · wk-form4_1718914999.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001411690-23-000057 · wf-form4_168694659605901.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:33 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 164,422 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036330 · doc4.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,422 Underlying: Common Stock · 164,422 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 23:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 194,986 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001209191-22-011920 · doc4.xml · derivative · entry 1 Rajkovic Aleksandar · CIK 0001909592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,986 Underlying: Common Stock · 194,986 shares Expires 2032-02-17 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on February 17, 2025, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.